Success Metrics

Clinical Success Rate
87.4%

Based on 26,589 completed trials

Completion Rate
87%(26589/30409)
Active Trials
4,822(12%)
Results Posted
48%(12649 trials)
Terminated
3,820(9%)

Phase Distribution

Ph not_applicable
6,814
16%
Ph phase_2
12,798
31%
Ph phase_1
8,093
20%
Ph phase_3
8,860
21%
Ph phase_4
4,142
10%
Ph early_phase_1
569
1%

Phase Distribution

8662

Early Stage

12798

Mid Stage

13002

Late Stage

Phase Distribution41276 total trials
Early Phase 1First-in-human
569(1.4%)
Phase 1Safety & dosage
8,093(19.6%)
Phase 2Efficacy & side effects
12,798(31.0%)
Phase 3Large-scale testing
8,860(21.5%)
Phase 4Post-market surveillance
4,142(10.0%)
N/ANon-phased studies
6,814(16.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.7%

26589 of 31782 finished

Non-Completion Rate

16.3%

5193 ended early

Currently Active

4822

trials recruiting

Total Trials

41,376

all time

Status Distribution
Active(6283)
Completed(26589)
Terminated(5193)
Other(3311)

Detailed Status

Completed26589
Terminated3820
Recruiting3402
unknown3196
Active, not recruiting1420
Withdrawn1373

Development Timeline

Analytics

Development Status

Total Trials
41376
Active
4822
Success Rate
87.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 1569 (1.4%)
Phase 18093 (19.6%)
Phase 212798 (31.0%)
Phase 38860 (21.5%)
Phase 44142 (10.0%)
N/A6814 (16.5%)

Trials by Status

not_yet_recruiting13383%
withdrawn13733%
suspended1150%
active_not_recruiting14203%
recruiting34028%
enrolling_by_invitation1230%
completed2658964%
terminated38209%
unknown31968%

Recent Activity

Clinical Trials (41,376)

Showing 20 of 41,376 trialsScroll for more
NCT07625215Phase 2

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

Not Yet Recruiting
NCT07045142Phase 3

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients

Recruiting
NCT07535034Phase 2

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

Recruiting
NCT07549490Not Applicable

Human Experimental Models of Pain (HEMP)

Not Yet Recruiting
NCT07504601Phase 2

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

Not Yet Recruiting
NCT07735728Phase 1

A First-in-Human Study of ZE66-0205 in Healthy Volunteers

Not Yet Recruiting
NCT07111065Phase 2

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Recruiting
NCT07389044Phase 1

A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B

Recruiting
NCT06616194Phase 3

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Active Not Recruiting
NCT07089043Phase 2

A Study in Subjects With Neurogenic Orthostatic Hypotension

Recruiting
NCT07174336Phase 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Recruiting
NCT07054515Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

Recruiting
NCT07601425Phase 1

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

Recruiting
NCT07610473Phase 2

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Recruiting
NCT06034743Phase 3

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Completed
NCT06843187Phase 2

Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)

Terminated
NCT07226141Phase 1

Valproate for the Treatment of Residual Amblyopia

Recruiting
NCT05815797Phase 2

Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis

Recruiting
NCT05787327Phase 2

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

Recruiting
NCT06948097Phase 1

Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
41,376